top of page

Phase I-Ready Biopharmaceutical Asset Targeting High-Growth Markets

Listing Code:

XYPH1D

State:

Not Disclosed

Category:

Pharmaceuticals & Supplements

Asking Price:

-

Revenue:

-

XYPH1D
Asset Overview

PRIME exits and American Healthcare Capital are pleased to exclusively present a Phase I-ready biopharmaceutical asset with significant potential in multiple high-growth therapeutic areas. Developed by an experienced team, this bifunctional peptide therapy addresses critical unmet needs in orphan indications such as pulmonary arterial hypertension (PAH) and sarcoidosis, with expansion opportunities into broader markets like chronic obstructive pulmonary disease (COPD) with cachexia, congestive heart failure (CHF) with cachexia, oncology, HIV-associated lipodystrophy, mild cognitive impairment (MCI) and MASH.

This therapy’s innovative mechanism of action combines growth hormone-releasing factor (GRF) and vasoactive intestinal peptide (VIP) properties, delivering anti-inflammatory, cardioprotective, pneumoprotective, lipolytic and anabolic benefits. Both peptides have been validated in clinical setting in cardio-pulmonary indications.

The asset is protected by patents in over 30 countries, including the U.S. and EU, and is primed for clinical development with Canadian IND approval secured. The IP expires in 2037 and can be extended.

Manufacturing processes for the asset are simple and highly scalable, with low costs of goods, ensuring strong margins.

The asset’s strong market potential is bolstered by opportunities to capture value in orphan indications and broader therapeutic areas with significant patient populations and high unmet needs, which can be developed in sequence to significantly reduce the clinical risk.

This opportunity is ideal for strategic or financial buyers seeking to add a first-in-class therapy to their pipeline. The seller is open to various transaction structures, including licensing, co-development, or acquisition.

Asking Price

The asking price for this opportunity is to be determined, and all competitive offers will be considered.

Inquire About This Listing:

In order to learn more about our listing, you must:

1. Complete a Buyer Profile:

This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard.

YOU ONLY NEED TO COMPLETE A BUYER PROFILE ONCE. 

2. Sign NDA with Listing Code:

To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.

Listing Code:

XYPH1D

Listing Title:

Phase I-Ready Biopharmaceutical Asset Targeting High-Growth Markets

Heading 4

Contact the Team

Jack Eskenazi American Healthcare Capital

Jack Eskenazi

President/Founder

American HealthCare Capital

Dr. Allen Nazeri DDS MBA.jpg

Dr. Allen Nazeri 

Managing Partner

PRIME exits

Join our mailing list to receive our latest news, and listings.

Thanks for submitting!

About us
 

PRIME exits is a registration pending trademark for Nazeri & Company LLCan independent affiliate of American Healthcare Capital. Nazeri & Company, Co. Ltd. is an international subsidiary of Nazeri & Company LLC. We are a merger and acquisition advisory firm focused on the healthcare industry with a network of 50+ M&A analysts and advisors. 

 

Locations

Los Angeles

Las Vegas

Bangkok

Vancouver, BC

Milan, Italy

Contact us

 

1-800- 424-3388 HEAD OFFICE

1-310-625-7889 Jack Eskenazi

1-702-506-3392 Dr. Allen Nazeri 

Valuation Team

Jack@ahcteam.com

Allen@ahcteam.com

Allen@pexits.com

Prime exits Bar code
Association Corporate Growth Logo
PRIME exits member masource-logo
CM&AP PRIME exits
bottom of page